Search - tctmd.com

Displaying 1 - 20 of 28

Sort: Relevancy | Date

Novel CRISPR-Cas9 Therapy Slows ATTR-CM Progression

News Conference News AHA 2024

Novel CRISPR-Cas9 Therapy Slows ATTR-CM Progression

Yael L. Maxwell

November 20, 2024

First-line Catheter Ablation Works for Post-MI VT Suppression: VANISH2

News Conference News AHA 2024

First-line Catheter Ablation Works for Post-MI VT Suppression: VANISH2

November 16, 2024

Few Patients Under 65 Get TAVI: Those Who Do Are Especially Sick

News Conference News TCT 2024

Few Patients Under 65 Get TAVI: Those Who Do Are Especially Sick

Yael L. Maxwell

November 07, 2024

Pooled All-Female Analysis Support Benefits of TAVI Over SAVR

News Conference News TCT 2024

Pooled All-Female Analysis Support Benefits of TAVI Over SAVR

November 01, 2024

In-Hospital Mortality Higher When Female CABG Patients Have Male Surgeons

News Conference News EACTS 2024

In-Hospital Mortality Higher When Female CABG Patients Have Male Surgeons

Yael L. Maxwell

October 14, 2024

MACE in CV Trials: Has the Outcome Outlived Its Role?

News Conference News EACTS 2024

MACE in CV Trials: Has the Outcome Outlived Its Role?

Yael L. Maxwell

October 11, 2024

Biomarker and Echo Data Bolster Vutrisiran’s Promise in ATTR-CM

News Conference News HFSA 2024

Biomarker and Echo Data Bolster Vutrisiran’s Promise in ATTR-CM

October 04, 2024

FINEARTS-HF: New Analyses Ask, Who Benefits Most From Finerenone?

News Conference News HFSA 2024

FINEARTS-HF: New Analyses Ask, Who Benefits Most From Finerenone?

Michael O'Riordan

October 02, 2024

Endometriosis and CV Risk: Link Needs Further Attention and Research

News Conference News ESC 2024

Endometriosis and CV Risk: Link Needs Further Attention and Research

Yael L. Maxwell

September 12, 2024

Balloon-Expandable TAVI Superior to SAVR in Women at 1 Year: RHEIA

News Conference News ESC 2024

Balloon-Expandable TAVI Superior to SAVR in Women at 1 Year: RHEIA

September 04, 2024

FINEARTS-HF: Benefit of Finerenone Extends to HFmrEF and HFpEF Patients

News Conference News ESC 2024

FINEARTS-HF: Benefit of Finerenone Extends to HFmrEF and HFpEF Patients

Michael O'Riordan

September 01, 2024

Three Common Biomarkers Closely Tied to Women’s 30-Year Risk of CV Events

News Conference News ESC 2024

Three Common Biomarkers Closely Tied to Women’s 30-Year Risk of CV Events

August 31, 2024

HELIOS-B: Novel ‘Silencer’ Agent Reduces Death, CV Events in ATTR-CM

News Conference News ESC 2024

HELIOS-B: Novel ‘Silencer’ Agent Reduces Death, CV Events in ATTR-CM

August 30, 2024

Incidental CAC Tied to Worse Outcomes in Systemic Inflammatory Diseases

News Conference News SCCT 2024

Incidental CAC Tied to Worse Outcomes in Systemic Inflammatory Diseases

July 21, 2024

Debate Continues on TAVI Choice for Women With Small Annuli

News Conference News EuroPCR 2024

Debate Continues on TAVI Choice for Women With Small Annuli

Yael L. Maxwell

May 14, 2024

Concomitant AF Procedures During Non-Mitral Surgery Less Likely in Women

News Conference News

Concomitant AF Procedures During Non-Mitral Surgery Less Likely in Women

Yael L. Maxwell

May 09, 2024

Ultralow-Temperature Cryoablation Promising for Monomorphic VT

News Conference News EHRA 2024

Ultralow-Temperature Cryoablation Promising for Monomorphic VT

April 12, 2024

Triglyceride-Lowering Therapies Provide Favorable Outcomes in Early Testing

News Conference News ACC 2024

Triglyceride-Lowering Therapies Provide Favorable Outcomes in Early Testing

Michael O'Riordan

April 12, 2024

KARDIA-2: Zilebesiran Drops BP on Top of Common Antihypertensives

News Conference News ACC 2024

KARDIA-2: Zilebesiran Drops BP on Top of Common Antihypertensives

April 11, 2024

Another Win for TAVI in Low-to-Intermediate Risk Patients

News Conference News ACC 2024

Another Win for TAVI in Patients at Low-to-Intermediate Risk: DEDICATE-DZHK6

Yael L. Maxwell

April 08, 2024

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.